<DOC>
	<DOCNO>NCT00605891</DOCNO>
	<brief_summary>The purpose study identify optimal once-daily dose CHF 4226 develop treatment patient COPD .</brief_summary>
	<brief_title>Dose Finding Study CHF 4226 Treating Patients With COPD</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>Patient sign IRB/Ethics Committeeapproved Informed Consent form Patient male nonpregnant female age 40 75 year , inclusive Patient current past smoke history least 15 packyears Patient clinical diagnosis COPD accordance recommendation National Heart Lung Blood Institute/World Health Organization ( NHLBI/WHO ) Global Initiative Chronic Obstructive Lung Disease ( GOLD ) Patient meet follow requirement FEV1 albuterol reversibility test ( i.e. , 30 minute follow 200 mcg ( meter dose ) albuterol/salbutamol pMDI ) : FEV1 least 0.9L FEV1 40 % 70 % , inclusive , patient 's predict normal value Change FEV1 &gt; 4 % patient 's predict normal value If change FEV1 &lt; 4 % patient 's predict normal value , requirement must meet retesting runin period , least 24 hour prior Day 1 FEV1/FVC &lt; 70 % Patient history asthma , allergic rhinitis , atopy Patient blood eosinophil count &gt; 500/microliter Patient COPD exacerbation lower respiratory tract infection within 8 week prior screen , runin period , result use antibiotic , oral parenteral corticosteroid Patient inhale corticosteroid initiate , effective dose change , within 4 week prior screen runin period Patient uncontrolled cardiovascular ( e.g. , uncontrolled hypertension ) , respiratory , hematologic , immunologic , renal , neurologic , hepatic , endocrine ( e.g. , uncontrolled diabetes mellitus ) disease , condition might , judgment Investigator , place patient undue risk potentially compromise result interpretation study Patient history coronary artery disease , cerebrovascular disease , cardiac arrhythmia Patient concomitant disease poor prognosis ( e.g. , cancer ) Patient serum potassium value ≤ 3.5 mEq/L &gt; 5.5mEq/L and/or fast serum glucose value ≥ 140 mg/dL Patient abnormal QTc Fridericia interval value Screening visit ECG test ( i.e. , &gt; 450 msec male &gt; 470 msec female ) Patient develop Cor Pulmonale Patient receive long term oxygen therapy , i.e. , ≥ 16 hours/24hour period , every day Patient know intolerance/hypersensitivity Beta2adrenergic agonist , propellant gases/excipients Patient receive treatment tricyclic antidepressant monoamine oxidase inhibitor ( MAOI ) Patient receive liveattenuated virus vaccination within two week prior screen runin Patient pregnant lactate female , female risk pregnancy ( i.e. , use adequate contraceptive method ) Patient mentally legally incapacitated Patient participate another investigational study within 30 day prior screen Patient abuse alcohol substance Patient potentially noncompliant unable perform require outcome measurement protocol</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2010</verification_date>
</DOC>